AI-assisted international press reviewPress review

Johnson & Johnson Launches ACUVUE OASYS MAX 2-Week Contact Lenses in Europe

Johnson & Johnson has announced CE marking for its ACUVUE OASYS MAX 2-Week contact lenses, which promise enhanced comfort and visual clarity through advanced technologies. Set to launch in Europe by the end of 2026, this product aims to meet the growing needs of digital device users while providing a seamless transition for existing lens wearers. Key features include a blue light filter, moisture retention technology, and UV protection, reinforcing the company's commitment to innovation in eye health.

Source: J&j - 10 September 2026

GSK Receives Approval for Pre-filled Syringe of Shingrix Vaccine in Japan

GSK announces that the Japanese Ministry of Health has approved a new pre-filled syringe presentation of its shingles vaccine, Shingrix, making administration easier. This innovation addresses a growing need, as one million cases of shingles are reported annually in Japan, with increased risk among the elderly and immunocompromised individuals.

Source: Gsk, published under the title "GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syring..." - 10 September 2026

Bayer Launches Phase II Study on GIRK4 Inhibitor for AFib Treatment

Bayer has announced the initiation of a Phase II clinical study for BAY 3670549, a selective GIRK4 channel inhibitor that could revolutionize the treatment of atrial fibrillation (AFib), a cardiac arrhythmia affecting millions. This study aims to evaluate the efficacy and safety of this treatment compared to a placebo, potentially offering a rapid alternative to electrical cardioversion, the current standard method. With this advancement, Bayer reinforces its commitment to innovation in the cardiovascular field, addressing an urgent need for effective and well-tolerated treatments for patients suffering from AFib.

Source: Bayer, published under the title "Bayer initiates Phase II study of investigational GIRK4 inhi..." - 9 September 2026

Bayer and Neste Partner to Develop Winter Canola for Biofuels

This commercial agreement between Bayer and Neste aims to increase the production of winter canola in the Southern Great Plains of the United States, in response to the growing demand for sustainable biofuels. The newgold® winter canola will be cultivated to provide raw materials for renewable diesel and sustainable aviation fuel, while offering farmers a new profit opportunity and improving land use.

Source: Bayer, published under the title "Bayer and Neste close commercial agreement to jointly scale ..." - 9 September 2026

Johnson & Johnson Unveils Major Advances in Multiple Myeloma Treatment

At the annual meeting of the International Myeloma Society, Johnson & Johnson presented over 35 abstracts on its innovative therapies for multiple myeloma, highlighting promising results and the ambition to transform this complex disease into a manageable, even curable condition. The analyses include data on approved and developing treatments, emphasizing the importance of an early and personalized approach to improve patient outcomes.

Source: J&j - 9 September 2026

25 Years of Expanding Access to Cancer Care: Progress and Challenges

This article outlines the advancements made over the past 25 years to improve access to cancer care, highlighting technological innovations and health policies that have transformed the treatment landscape. It also addresses ongoing challenges and future prospects to ensure equitable access to oncology care.

Source: Novartis, published under the title "25 years of expanding access to cancer care" - 8 September 2026

Novartis Updates on HARBOR Study of Del-desiran for Myotonic Dystrophy Type 1

Novartis' HARBOR study of del-desiran for myotonic dystrophy type 1 did not meet its primary endpoint, but encouraging results were observed in secondary analyses. The company is evaluating next steps for the development of this innovative treatment while maintaining its sales growth forecasts for the coming years.

Source: Novartis, published under the title "Novartis provides update on delpacibart etedesiran (del-desi..." - 8 September 2026

Abbott Receives FDA Approval for TactiFlex™ Duo Ablation Catheter

Abbott's TactiFlex™ Duo ablation catheter, equipped with Sensor Enabled™ technology, combines pulsed field ablation and radiofrequency energy to treat complex cases of atrial fibrillation. This FDA approval enhances Abbott's portfolio of cardiac ablation technologies, providing physicians with advanced tools to improve the safety and effectiveness of treatments.

Source: Abbott, published under the title "Abbott Receives FDA Approval For Its TactiFlex™ Duo Ablation..." - 8 September 2026

Johnson & Johnson Highlights Key Neuropsychiatry Data at Psych Congress 2026

At the Psych Congress 2026, Johnson & Johnson presented crucial data on CAPLYTA® and other treatments for mood disorders, emphasizing the importance of clinical research and real-world data to enhance therapeutic options. The event aims to strengthen the understanding of treatment challenges in the field of neuropsychiatry.

Source: J&j, published under the title "Johnson & Johnson spotlights new neuropsychiatry data across..." - 8 September 2026

Novartis Reports Lp(a)HORIZON Trial Results on Pelacarsen Treatment

The Lp(a)HORIZON clinical trial conducted by Novartis revealed that while the pelacarsen treatment successfully reduced lipoprotein (a) levels, it did not decrease the risk of major cardiovascular events in patients with established cardiovascular disease. These findings underscore the importance of ongoing research into cardiovascular risk factors and potential treatments, as lipoprotein (a) remains a medical challenge without an approved solution.

Source: Novartis, published under the title "Novartis announces Lp(a)HORIZON Phase III topline results fo..." - 5 September 2026

Etcamah and CDK4/6 Inhibitor: Major Breakthrough for HR-Positive Breast Cancer

The FDA's approval of Etcamah in combination with a CDK4/6 inhibitor marks a significant advancement in the treatment of advanced HR-positive breast cancer, providing a new therapeutic strategy for patients with ESR1 mutations. Results from the SERENA-6 trial demonstrate a 56% reduction in the risk of disease progression, highlighting the importance of early intervention in managing this disease. A companion diagnostic test has also been approved to detect these mutations, reinforcing the personalized approach to treatment.

Source: Astrazeneca, published under the title "Etcamah in combination with a CDK4/6 inhibitor approved in t..." - 5 September 2026

Johnson & Johnson to Present at Deutsche Bank 2026 Healthcare Summit

Johnson & Johnson announces its participation in the Deutsche Bank 2026 Healthcare Summit, where management will engage in an informal discussion. The live audio webcast will be accessible on the company's investor relations website, with a replay scheduled 48 hours after the event.

Source: J&j, published under the title "Johnson & Johnson to Participate in the Deutsche Bank 2026 H..." - 3 September 2026

Bayer Launches Innovative Seed and Crop Protection Pipeline

Bayer announces the start of commercialization for two flagship products and plans further launches in the coming years, integrating crop protection solutions and genetically modified seeds to address contemporary agricultural challenges. With over 15 new modes of action in research, the company is leveraging AI to transform agriculture and enhance crop yields.

Source: Bayer, published under the title "Bayer advances combined seed and crop protection pipeline an..." - 2 September 2026

AstraZeneca Finalizes Licensing Agreement for Lung Cancer Treatment Zegfrovy

AstraZeneca has announced the finalization of an exclusive licensing agreement for Zegfrovy, an EGFR inhibitor aimed at enhancing treatment options for lung cancer patients. This drug, already approved in China, is set to launch in the United States by the end of 2026, with an initial investment of $600 million for its development. Zegfrovy specifically targets exon 20 insertion mutations of the EGFR, a condition that presents an urgent need for new therapies.

Source: Astrazeneca, published under the title "AstraZeneca completes global license agreement for oral EGFR..." - 1 September 2026

Tagrisso and Orpathys: Significant Advances in Lung Cancer Treatment

Results from the Phase III SANOVO trial in China show that the combination of Tagrisso and Orpathys significantly improves progression-free survival in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations and MET overexpression, reinforcing Tagrisso's role as a foundational treatment. These findings are part of a series of clinical trials aimed at transforming therapeutic approaches for this patient population.

Source: Astrazeneca, published under the title "Tagrisso plus Orpathys demonstrated statistically significan..." - 1 September 2026

Enhertu and Pertuzumab Supply: Major Advancement for HER2-Positive Breast Cancer

The EU's approval of Enhertu in combination with pertuzumab marks a significant advancement in the treatment of HER2-positive metastatic breast cancer, offering a median progression-free survival of over three years, according to results from the DESTINY-Breast09 trial. This new therapeutic option could transform care standards for patients, addressing an urgent need for improved clinical outcomes in this aggressive disease.

Source: Astrazeneca, published under the title "Enhertu plus pertuzumab approved in the EU as first new regi..." - 1 September 2026

Novartis Reports Promising Results for Remibrutinib in Multiple Sclerosis

Phase III clinical trials REMODEL-1/-2 demonstrate that remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, significantly reduces relapse rates in patients with relapsing multiple sclerosis while showing a favorable safety profile. Novartis plans to submit these results to health authorities for global approval and to present them at the MSToronto2026 congress.

Source: Novartis, published under the title "Novartis remibrutinib, a high-efficacy oral BTK inhibitor, s..." - 1 September 2026

GSK Advances mRNA Flu Vaccine to Phase III After Promising Phase II Results

GSK has announced encouraging results for its mRNA flu vaccine candidate, demonstrating immune responses superior to traditional vaccines. A Phase III trial is scheduled for September 2026, aiming to target key antigens of the influenza virus, with hopes of improving protection against this seasonal illness that affects millions each year.

Source: Gsk, published under the title "GSK to advance mRNA seasonal flu vaccine candidate to phase ..." - 1 September 2026

Johnson & Johnson Announces Conference Call for Q3 2026 Results

On October 13, 2026, Johnson & Johnson will host a conference call to discuss its third-quarter financial results, led by its CEO and other executives. Investors will be able to access the call by phone or through the company's website, with a replay available after the event.

Source: J&j - 1 September 2026

Finerenone: A Hope to Slow Kidney Decline in Hypertensive Patients

A subgroup analysis from the FIND-CKD study reveals that finerenone slows the decline of kidney function and reduces cardiovascular risks in patients with hypertensive nephropathy, marking a significant advancement in a field where treatment options are limited. The results, presented at the European Society of Cardiology Congress, underscore the importance of this treatment in managing chronic kidney diseases related to hypertension.

Source: Bayer, published under the title "Finerenone slowed kidney function decline and reduced kidney..." - 30 August 2026